Inclusion Criteria:  Age ≥18 years at enrollment Patients willing and able to provide written informed consent for data transmission. For patients who are not legally competent to sign this informed consent for data transmission exceptions/special cases are defined (details provided in the study protocol) Patients with primary intracranial hemorrhage as confirmed with CT or MRI. Patients under effective anticoagulation treatment with rivaroxaban or apixaban at the time of admission, according to the judgement of treating physician and determined using Point-of-care (PoC) anti-factor Xa (fXa) assays or laboratory-based anti-fXa measurement. Patients treated with andexanet alfa Signed informed consent as soon as possible after start of symptoms of initial ICH event, but before discharge  Exclusion Criteria:  Start of symptoms of initial ICH event > 24 h before admission to hospital